Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Links Up with US Biotech Potenza on Immuno-Oncology
Astellas Pharma said on April 22 that it has struck an exclusive R&D collaboration deal with US biotech startup Potenza Therapeutics Inc. to build a portfolio of immuno-oncology therapeutics. Under the deal, the two partners will seek to develop new…
To read the full story
Related Article
- Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
- Development of Novel Myeloid Leukemia Drug Gilteritinib Makes Progress: Astellas
December 12, 2016
BUSINESS
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
March 4, 2026
- Efient AGs Launched Just Ahead of 3-Month Supply Deadline
March 4, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…